Lingyu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lingyu Li has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Kaixiang Yan
School of Information Science and Engineering, Yunnan University, Kunming, China
2 shared publications - Xiaohui Zhan
Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China
2 shared publications - Yong Zhao
Department of Pathology, Chongqing Medical University
2 shared publications Changhong Yang
Department of Bioinformatics, Chongqing Medical University, Chongqing 400016, China
1 shared publicationFuxin Zhong
Chongqing Medical University
1 shared publication- Fuxin Zhong
Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- 6 November 2025
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 113
IHC-IS4BC: A supervised dataset for pathological image segmentation based on IHC-staining slides of breast cancer
- 6 November 2025
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 113
IHC-IS4BC: A supervised dataset for pathological image segmentation based on IHC-staining slides of breast cancer
- 22 February 2024
- Published by Springer Nature in Signal, Image and Video Processing
- Vol. 18 (4) , 3705-3713
BIS5k: a large-scale dataset for medical segmentation task based on HE-staining images of breast cancer
- 22 February 2024
- Published by Springer Nature in Signal, Image and Video Processing
- Vol. 18 (4) , 3705-3713
BIS5k: a large-scale dataset for medical segmentation task based on HE-staining images of breast cancer
- 1 March 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 180, 12-23
Platonin protects against cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasomes via BNIP3/LC3 signaling mediated autophagy
- 1 March 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 180, 12-23
Platonin protects against cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasomes via BNIP3/LC3 signaling mediated autophagy
- Open Access
- 5 January 2022
- Published by Springer Nature in Research Square
The Valuable Role of Armc1 in Invasive Breast Cancer as a Novel Biomarker
Background: Invasive breast carcinoma (BRCA) is a common type of breast cancer with high incidence in clinics, so it is significant to find an effective biomarker for BRCA diagnosis and treatment. Although some Armadillo (Arm)-repeat proteins families are confirmed to be biomarkers in cancers, the role of Armadillo repeat-containing 1 (ARMC1) in BRCA remains unknown.Methods: We analyzed the ARMC1 expression in normal breast tissues and BRCA samples, and its association with overall survival by the public database. χ² test evaluated the risks associated with ARMC1 expression in TCGA-BRCA patient samples. The ARMC1 mutations in BRCA were explored in the cBioportal database. Besides, the GO and KEGG analysis was used to explore the potential signaling pathways of ARMC1 in BRCA. Lastly, Immunohistochemistry and immunohistochemistry were performed to validate the ARMC1 expression in BRCA.Results: ARMC1 level in tumor sample was significantly higher than that in normal tissue, and it was also related to lower survival. The factors in clinical patients such as tumor stage and grade and histology were associated with ARMC1 expression. There were 32% of ARMC1 genetic mutations in BRCA, and the amplification and high expression made up the majority of them. Also, ARMC1 might regulate BRCA by involving in the cell cycle. Increased ARMC1 expression was found in clinical breast carcinoma tissues by our confirmatory experiments.Conclusions: All the results revealed that ARMC1 may play a significant role in BRCA as a biomarker, it provides valuable clues for the treatment and diagnosis of invasive breast cancer.
- 5 January 2022
- Published by Springer Nature in Research Square
Open AccessThe Valuable Role of Armc1 in Invasive Breast Cancer as a Novel Biomarker
Background: Invasive breast carcinoma (BRCA) is a common type of breast cancer with high incidence in clinics, so it is significant to find an effective biomarker for BRCA diagnosis and treatment. Although some Armadillo (Arm)-repeat proteins families are confirmed to be biomarkers in cancers, the role of Armadillo repeat-containing 1 (ARMC1) in BRCA remains unknown.Methods: We analyzed the ARMC1 expression in normal breast tissues and BRCA samples, and its association with overall survival by the public database. χ² test evaluated the risks associated with ARMC1 expression in TCGA-BRCA patient samples. The ARMC1 mutations in BRCA were explored in the cBioportal database. Besides, the GO and KEGG analysis was used to explore the potential signaling pathways of ARMC1 in BRCA. Lastly, Immunohistochemistry and immunohistochemistry were performed to validate the ARMC1 expression in BRCA.Results: ARMC1 level in tumor sample was significantly higher than that in normal tissue, and it was also related to lower survival. The factors in clinical patients such as tumor stage and grade and histology were associated with ARMC1 expression. There were 32% of ARMC1 genetic mutations in BRCA, and the amplification and high expression made up the majority of them. Also, ARMC1 might regulate BRCA by involving in the cell cycle. Increased ARMC1 expression was found in clinical breast carcinoma tissues by our confirmatory experiments.Conclusions: All the results revealed that ARMC1 may play a significant role in BRCA as a biomarker, it provides valuable clues for the treatment and diagnosis of invasive breast cancer.
- RetractedOpen Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 1740295
[Retracted] The Valuable Role of ARMC1 in Invasive Breast Cancer as a Novel Biomarker
Background. Invasive breast carcinoma (BRCA) is a common type of breast cancer with a high clinical incidence. Thus, it is significant to find effective biomarkers for BRCA diagnosis and treatment. Although some members of armadillo (ARM) repeat family of proteins are confirmed to be biomarkers in cancers, the role of armadillo repeat‐containing 1 (ARMC1) in BRCA remains unknown. Methods. We firstly analyzed the ARMC1 expression in normal breast tissues and BRCA samples and its association with overall survival by the public database. Next, the χ2 test was used to evaluate the prognostic significance of ARMC1 expression in TCGA‐BRCA patient samples. The ARMC1 mutations in BRCA were explored in the cBioportal database. Besides, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to explore the biological functions of ARMC1 in BRCA. Finally, immunohistochemistry and immunofluorescence staining were performed to validate the ARMC1 expression in BRCA. Results. ARMC1 expression in tumor samples was significantly higher than that in normal tissues, and higher expression of ARMC1 was related to lower survival. Moreover, the tumor stage and histology of BRCA patients were associated with ARMC1 expression. ARMC1 genetic mutations occurred in 32% of BRCA patients, and the amplification and high expression of ARMC1 accounted for most of them. Furthermore, functional enrichment analysis suggested that ARMC1 might be involved in the cell cycle in BRCA. Ultimately, increased ARMC1 expression was found in clinical breast carcinoma tissues by our confirmatory experiments. Conclusions. ARMC1 may play a significant role in BRCA and act as a biomarker, which provides valuable clues for the treatment and diagnosis of BRCA.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 1740295
RetractedOpen Access[Retracted] The Valuable Role of ARMC1 in Invasive Breast Cancer as a Novel Biomarker
Background. Invasive breast carcinoma (BRCA) is a common type of breast cancer with a high clinical incidence. Thus, it is significant to find effective biomarkers for BRCA diagnosis and treatment. Although some members of armadillo (ARM) repeat family of proteins are confirmed to be biomarkers in cancers, the role of armadillo repeat‐containing 1 (ARMC1) in BRCA remains unknown. Methods. We firstly analyzed the ARMC1 expression in normal breast tissues and BRCA samples and its association with overall survival by the public database. Next, the χ2 test was used to evaluate the prognostic significance of ARMC1 expression in TCGA‐BRCA patient samples. The ARMC1 mutations in BRCA were explored in the cBioportal database. Besides, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to explore the biological functions of ARMC1 in BRCA. Finally, immunohistochemistry and immunofluorescence staining were performed to validate the ARMC1 expression in BRCA. Results. ARMC1 expression in tumor samples was significantly higher than that in normal tissues, and higher expression of ARMC1 was related to lower survival. Moreover, the tumor stage and histology of BRCA patients were associated with ARMC1 expression. ARMC1 genetic mutations occurred in 32% of BRCA patients, and the amplification and high expression of ARMC1 accounted for most of them. Furthermore, functional enrichment analysis suggested that ARMC1 might be involved in the cell cycle in BRCA. Ultimately, increased ARMC1 expression was found in clinical breast carcinoma tissues by our confirmatory experiments. Conclusions. ARMC1 may play a significant role in BRCA and act as a biomarker, which provides valuable clues for the treatment and diagnosis of BRCA.
- 1 October 2020
- Published by Elsevier in Brain Research
- Vol. 1745, 146948
Sestrin2 promotes angiogenesis to alleviate brain injury by activating Nrf2 through regulating the interaction between p62 and Keap1 following photothrombotic stroke in rats
- 1 October 2020
- Published by Elsevier in Brain Research
- Vol. 1745, 146948
Sestrin2 promotes angiogenesis to alleviate brain injury by activating Nrf2 through regulating the interaction between p62 and Keap1 following photothrombotic stroke in rats